FDA advisers question effect of GSK's Advair

An FDA advisory panel declined to say if GlaxoSmithKline's heart drug Advair should be approved, saying there was not enough evidence of its effectiveness in increasing survival in patients with chronic obstructive pulmonary disease. The panel did note that a study showed a "meaningful decrease" in COPD exacerbations.

View Full Article in:

MarketWatch · Wall Street Journal (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Wayzata, MN
Director of Clinical Research
Regenesis Biomedical, Inc.
Scottsdale, AZ
Meridian Health Plan
Detroit, MI
Assistant Vice President - Dental Director
Bridgewater, NJ